New antibody combo shows promise for Hard-to-Treat cancers
NCT ID NCT05082610
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if the drug shrinks tumors. While not a cure, it aims to control the disease by boosting the immune system against cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
-
Smilow Cancer Hospital - Yale New Heaven Health
New Haven, Connecticut, 06511, United States
-
Stanford Cancer Institute
Palo Alto, California, 94304, United States
-
The City of Hope National Medical Center
Duarte, California, 91010, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UTSW Medical Center
Dallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can your own immune cells beat advanced cancer?
- Could sitting up make radiation therapy more comfortable?
- Can we predict dangerous side effects when combining radiation and immunotherapy?
- Family history as a shield: can culturally tailored guidance cut cancer risk?
- A simple screening program could transform cancer aftercare